Haifa Kathrin Al-Ali (Haifa-Kathrin Al-Ali)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 8

Top Topics

Immune Response

Acute Lymphoblastic Leukemia

Prognostic Factors

Top Venues

Future oncology (London, England)

Annals of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Francesca Palandri, Haifa Kathrin Al-Ali, Paola Guglielmelli, Mike W Zuurman, Rajendra Sarkar, Vikas K Gupta
Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study. Cancers 15 (10) (2023)
Saskia Hell, Madlen Jentzsch, Georg-Nikolaus Franke, Nadja Jäkel, Susann Schulze, Jeanett Edelmann, Kolja Nenoff, Nora Grieb, Veljko Jeremic, Michael Cross, Sabine Leiblein, Enrica Bach, Wolfram Pönisch, Haifa Kathrin Al-Ali, Sebastian Schwind, Uwe Platzbecker, Thoralf Lange, Dietger Niederwieser, Vladan Vucinic
Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning-Eudract #: 2007-002420-15. Bone marrow transplantation 57 (5) (2022)
Sabrina Jotschke, Susann Schulze, Nadja Jäkel, Beatrice Ludwig-Kraus, Robby Engelmann, Frank Bernhard Kraus, Christina Zahn, Nicole Nedlitz, Gabriele Prange-Krex, Johannes Mohm, Bettina Peuser, Maik Schwarz, Claudia Spohn, Timo Behlendorf, Mascha Binder, Christian Junghanss, Sebastian Böttcher, Haifa Kathrin Al-Ali
Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO). Cancers 14 (6) (2022)
Claire N Harrison, Vikas K Gupta, Aaron T Gerds, Raajit K Rampal, Srdan Verstovsek, Moshe Talpaz, Jean-Jacques Kiladjian, Ruben A Mesa, Andrew T Kuykendall, Alessandro Maria Maria Vannucchi, Francesca Palandri, Sebastian Grosicki, Timothy Devos, Eric Jourdan, Marielle J Wondergem, Haifa Kathrin Al-Ali, Veronika Buxhofer-Ausch, Alberto Álvarez-Larrán, Andrea Patriarca, Marina Kremyanskaya, Adam J Mead, Sanjay Akhani, Yuri Sheikine, Gozde Colak, John O Mascarenhas
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis. Future oncology (London, England) 18 (27) (2022)
Srdan Verstovsek, Haifa Kathrin Al-Ali, John O Mascarenhas, Andrew Charles Perkins, Alessandro Maria Maria Vannucchi, Sanjay R Mohan, Bart L Scott, Dariusz Woszczyk, Steffen Koschmieder, Regina García-Delgado, Rejtő László, Jesse S McGreivy, Wayne P Rothbaum, Jean-Jacques Kiladjian
BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis. Future oncology (London, England) (2022)
Francisco Cervantes, David M Ross, Atanas Radinoff, Francesca Palandri, Alexandr Myasnikov, Alessandro M Vannucchi, Pierre Zachee, Heinz Gisslinger, Norio Komatsu, Lynda Foltz, Francesco Mannelli, Francesco Passamonti, Geralyn Gilotti, Islam Sadek, Ranjan Tiwari, Evren Zor, Haifa Kathrin Al-Ali
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. Leukemia 35 (12) (2021)
Haifa Kathrin Al-Ali, Martin Griesshammer, Lynda Foltz, Giuseppe A Palumbo, Bruno Martino, Francesca Palandri, Anna Marina Liberati, Philipp le Coutre, Carmen García-Hernández, Andrey Zaritskey, Renato Tavares, Vikas Gupta, Pia Raanani, Pilar Giraldo, Mathias Hänel, Daniela Damiani, Tomasz Sacha, Catherine Bouard, Carole Paley, Ranjan Tiwari, Francesco Mannelli, Alessandro M Vannucchi
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. British journal of haematology 189 (5) (2020)
Christin Le Hoa Tran, Nadja Jäkel, Marcus Bauer, Alexander Emmer, Claudia Wickenhauser, Haifa Kathrin Al-Ali
Aggressive systemic mastocytosis: a diagnostic challenge in a patient with myotonic dystrophy type 2: a case report. Annals of hematology 98 (12) (2019)